497 related articles for article (PubMed ID: 12937692)
21. FDG PET: advantages for staging the mediastinum?
Franzius C
Lung Cancer; 2004 Aug; 45 Suppl 2():S69-74. PubMed ID: 15552784
[TBL] [Abstract][Full Text] [Related]
22. F-18 fluorodeoxyglucose positron emission tomography in the non-invasive staging of non-small cell lung cancer.
Berlangieri SU; Scott AM; Knight SR; Fitt GJ; Hennessy OF; Tochon-Danguy HJ; Clarke CP; McKay WJ
Eur J Cardiothorac Surg; 1999 Sep; 16 Suppl 1():S25-30. PubMed ID: 10536941
[TBL] [Abstract][Full Text] [Related]
23. Non-small cell lung cancer: dual-modality PET/CT in preoperative staging.
Antoch G; Stattaus J; Nemat AT; Marnitz S; Beyer T; Kuehl H; Bockisch A; Debatin JF; Freudenberg LS
Radiology; 2003 Nov; 229(2):526-33. PubMed ID: 14512512
[TBL] [Abstract][Full Text] [Related]
24. Positron emission tomography with selected mediastinoscopy compared to routine mediastinoscopy offers cost and clinical outcome benefits for pre-operative staging of non-small cell lung cancer.
Yap KK; Yap KS; Byrne AJ; Berlangieri SU; Poon A; Mitchell P; Knight SR; Clarke PC; Harris A; Tauro A; Rowe CC; Scott AM
Eur J Nucl Med Mol Imaging; 2005 Sep; 32(9):1033-40. PubMed ID: 15875178
[TBL] [Abstract][Full Text] [Related]
25. Cost-effectiveness of FDG-PET for the management of potentially operable non-small cell lung cancer: priority for a PET-based strategy after nodal-negative CT results.
Dietlein M; Weber K; Gandjour A; Moka D; Theissen P; Lauterbach KW; Schicha H
Eur J Nucl Med; 2000 Nov; 27(11):1598-609. PubMed ID: 11105815
[TBL] [Abstract][Full Text] [Related]
26. Test performance of positron emission tomography and computed tomography for mediastinal staging in patients with non-small-cell lung cancer: a meta-analysis.
Gould MK; Kuschner WG; Rydzak CE; Maclean CC; Demas AN; Shigemitsu H; Chan JK; Owens DK
Ann Intern Med; 2003 Dec; 139(11):879-92. PubMed ID: 14644890
[TBL] [Abstract][Full Text] [Related]
27. [Value of 18F-fluorodeoxyglucose positron emission tomography imaging in staging of non-small cell lung cancer].
Guan Y; He S; Dong J
Zhonghua Yi Xue Za Zhi; 2001 Oct; 81(19):1180-3. PubMed ID: 11769705
[TBL] [Abstract][Full Text] [Related]
28. Does whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography have an advantage over thoracic positron emission tomography for staging patients with lung cancer?
Aquino SL; Fischman AJ
Chest; 2004 Sep; 126(3):755-60. PubMed ID: 15364753
[TBL] [Abstract][Full Text] [Related]
29. 18F-FDG PET/Contrast-Enhanced CT for Initial Staging and Strategic Treatment of Non-Small Cell Lung Cancer: A Prospective Study.
Promteangtrong C; Kunawudhi A; Phadungrerk R; Iamsa-art C; Chotipanich C
J Med Assoc Thai; 2015 Oct; 98(10):1010-8. PubMed ID: 26638593
[TBL] [Abstract][Full Text] [Related]
30. Lymph node staging in lung cancer using [18F]FDG-PET.
Halter G; Buck AK; Schirrmeister H; Aksoy E; Liewald F; Glatting G; Neumaier B; Mühling B; Nüssle-Kügele K; Hetzel M; Sunder-Plassmann L; Reske SN
Thorac Cardiovasc Surg; 2004 Apr; 52(2):96-101. PubMed ID: 15103582
[TBL] [Abstract][Full Text] [Related]
31. Staging of mediastinal non-small cell lung cancer with FDG PET, CT, and fusion images: preliminary prospective evaluation.
Wahl RL; Quint LE; Greenough RL; Meyer CR; White RI; Orringer MB
Radiology; 1994 May; 191(2):371-7. PubMed ID: 8153308
[TBL] [Abstract][Full Text] [Related]
32. Mediastinal nodal staging of nonsmall cell lung cancer using integrated 18F-FDG PET/CT in a tuberculosis-endemic country: diagnostic efficacy in 674 patients.
Kim YK; Lee KS; Kim BT; Choi JY; Kim H; Kwon OJ; Shim YM; Yi CA; Kim HY; Chung MJ
Cancer; 2007 Mar; 109(6):1068-77. PubMed ID: 17311309
[TBL] [Abstract][Full Text] [Related]
33. Staging of lymph nodes with FDG dual-headed PET in patients with non-small-cell lung cancer.
Stokkel MP; Bakker PF; Heine R; Schlösser NJ; Lammers JW; Van Rijk PP
Nucl Med Commun; 1999 Nov; 20(11):1001-7. PubMed ID: 10572909
[TBL] [Abstract][Full Text] [Related]
34. Decision-tree sensitivity analysis for cost-effectiveness of chest 2-fluoro-2-D-[(18)F]fluorodeoxyglucose positron emission tomography in patients with pulmonary nodules (non-small cell lung carcinoma) in Japan.
Kosuda S; Ichihara K; Watanabe M; Kobayashi H; Kusano S
Chest; 2000 Feb; 117(2):346-53. PubMed ID: 10669673
[TBL] [Abstract][Full Text] [Related]
35. Improved radiologic staging of lung cancer with 2-[18F]-fluoro-2-deoxy-D-glucose-positron emission tomography and computed tomography registration.
Aquino SL; Asmuth JC; Alpert NM; Halpern EF; Fischman AJ
J Comput Assist Tomogr; 2003; 27(4):479-84. PubMed ID: 12886128
[TBL] [Abstract][Full Text] [Related]
36. Use of a dual-head coincidence camera and 18F-FDG for detection and nodal staging of non-small cell lung cancer: accuracy as determined by 2 independent observers.
Stevens H; Bakker PF; Schlösser NJ; van Rijk PP; de Klerk JM
J Nucl Med; 2003 Mar; 44(3):336-40. PubMed ID: 12620997
[TBL] [Abstract][Full Text] [Related]
37. Cost-effectiveness of FDG-PET for staging non-small cell lung cancer: a decision analysis.
Scott WJ; Shepherd J; Gambhir SS
Ann Thorac Surg; 1998 Dec; 66(6):1876-83; discussion 1883-5. PubMed ID: 9930463
[TBL] [Abstract][Full Text] [Related]
38. Mediastinal staging of non-small-cell lung cancer with positron emission tomography.
Chin R; Ward R; Keyes JW; Choplin RH; Reed JC; Wallenhaupt S; Hudspeth AS; Haponik EF
Am J Respir Crit Care Med; 1995 Dec; 152(6 Pt 1):2090-6. PubMed ID: 8520780
[TBL] [Abstract][Full Text] [Related]
39. FDG-PET in staging lung cancer: how does it change the algorithm?
Verhagen AF; Bootsma GP; Tjan-Heijnen VC; van der Wilt GJ; Cox AL; Brouwer MH; Corstens FH; Oyen WJ
Lung Cancer; 2004 May; 44(2):175-81. PubMed ID: 15084382
[TBL] [Abstract][Full Text] [Related]
40. Cost-effectiveness of hybrid PET/CT for staging of non-small cell lung cancer.
Schreyögg J; Weller J; Stargardt T; Herrmann K; Bluemel C; Dechow T; Glatting G; Krause BJ; Mottaghy F; Reske SN; Buck AK
J Nucl Med; 2010 Nov; 51(11):1668-75. PubMed ID: 21051648
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
